Clovis Oncology

Clovis Oncology is a small pharmaceutical company which mainly markets products for treatment in oncology.[1] Clovis was founded in 2009 and is headquartered in Boulder, Colorado.[2] The company is a publicly traded company on NASDAQ under the symbol "CLVS" [3] and is in the NASDAQ Biotechnology Index[4] with several products in its product pipeline.[5]

Pipeline

Its products include:

Rociletinib

The company was developing rociletinib,[6] as a treatment for non-small cell lung cancer.[1][7][8][9] A phase III trial was completed in April 2016[10] and had it been approved it would have competed with AstraZeneca's Tagrisso (osimertinib).[10] According to the company web site as of November 2016 the drug was no longer in development but they would continue to supply the drug to patients whose physicians had recommended continued treatment.[11]

Rucaparib

Rucaparib is a PARP inhibitor in Phase II and III clinical trials for advanced ovarian cancer.[12]

Lucitanib

Lucitanib is a VEGFR inhibitor.[13] it is also an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.[14] including for metastatic breast cancer.[15]

References

  1. 1 2 "Clovis Oncology: A Winning Or Losing Lottery Ticket?". Forbes. 2015-11-16. Retrieved 2016-01-04.
  2. ↑ "CLVS Profile". finance.yahoo.com.
  3. ↑ "Clovis Oncology Inc.". www.marketwatch.com. Retrieved 4 January 2016.
  4. ↑ "Overview NBI". nasdaq.com. Retrieved 4 January 2016.
  5. ↑ "Clovis Oncology - Products & Companion Diagnostics". Clovisoncology.com. 9 March 2015. Archived from the original on March 9, 2015. Retrieved 4 January 2016.
  6. ↑ Williams, Sean (23 December 2015). "A Festivus for the Invest in Us -- It's Time for the Airing of Grievances". Fox Business. Retrieved 4 January 2016.
  7. ↑ Wallace, Alicia. "Clovis Oncology stock bludgeoned after delay in cancer drug approval". www.denverpost.com. Retrieved 4 January 2016.
  8. ↑ "hClovis Oncology Announces Regulatory Update for Rociletinib NDA Filing". www.reuters.com. Retrieved 4 January 2016.
  9. ↑ "FDA Requests Additional Data for Rociletinib in EGFR T790M-Mutant NSCLC". OncLive. 2015-11-16. Retrieved 2016-01-04.
  10. 1 2 Investors doubt efficacy of Clovis lung cancer med rociletinib, shares off 11%. April 2016
  11. ↑ "About Clovis". Retrieved 18 November 2016.
  12. ↑ Rucaparib at Clovis
  13. ↑ Lucitanib at Clovis
  14. ↑ Soria; et al. (2014). "Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.". doi:10.1093/annonc/mdu390. PMID 25193991.
  15. ↑ A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer (FINESSE)

External links

This article is issued from Wikipedia - version of the 11/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.